Acuson Redwood holds the US Food and Drug Administration (FDA) approval and European CE-Mark. It expands the company’s Acuson portfolio, which consists of Sequoia and Juniper systems.
The system is portable and lightweight with multiple artificial intelligence (AI)-based tools for smart workflows and cardiology features.
Transducers integrated into the device include micro-pinless technology and single crystal transducers for improved image quality.
Acuson Redwood also comprises coherent image formation (CIF) technology for image quality and UltraArt Universal Image Processing for image choices.
Siemens Healthineers ultrasound head Robert Thompson said: “Chronic diseases often require more imaging and additional follow up which drives costs. To meet this challenge, we worked together with input from users to transform care delivery with the Acuson Redwood.
“This system is designed to deliver premium image quality, exceptional performance, and greater workflow efficiency within the constraints of limited resources and tightening budgets.”
Acuson Redwood comes with Contrast Enhanced Ultrasound (CEUS) and Shear wave Elastography applications for accurate detection and characterisation of lesions.
The applications are also said to minimise the need for invasive procedures.
Moreover, the system has been designed to provide a variety of cardiac assessments. It has a 2D quantitative tool, Velocity Vector Imaging (VVI), to examine global and regional myocardial motion and mechanics.
Additionally, the ultrasound device includes stress echo, along with wall motion scoring analysis and Left Ventricular Opacification (LVO) capability for cardiac contrast agent imaging.
Last month, Siemens introduced two computed tomography (CT) systems Somatom go.Sim and Somatom go.Open Pro, designed for radiation therapy planning.